Hypoparathyroidism
ICD-10 E20.0 · ICD-11 5A50.0

Treatment of Hypoparathyroidism in Pregnancy and Breastfeeding

Women with hypoparathyroidism who are pregnant or breastfeeding face considerable risk for both hypercalcaemia and hypocalcaemia. The physiological changes of gestation and the postpartum period alter calcium handling, making active monitoring and timely management adjustments essential throughout.

Clinical Setting

This protocol addresses hypoparathyroidism specifically in the context of pregnancy and lactation — two distinct phases that each carry their own calcium homeostasis challenges. Management must account for the transition between these phases, including the hormonal environment of lactation and its effects on calcium requirements.

Treatment Approach (Partial)

The core treatment involves activated vitamin D analogues and calcium supplementation, with the established pre-pregnancy regimen generally serving as the starting point after conception. The regimen is re-evaluated at key points — particularly around delivery and during lactation — as requirements typically shift during these transitions.

Full dosing strategy, adjustment criteria, monitoring intervals, and the complete management algorithm are available in the structured protocol →

Treatment Goals

Maintain ionised calcium and/or albumin-adjusted calcium levels at the lower end of the normal range throughout pregnancy and lactation.

Instant Access to Structured Evidence-Based Regimens

References

Pregnant and nursing women with HypoPT are at considerable risk for both hypercalcaemia and hypocalcaemia.

We suggest treatment with activated vitamin D analogues and calcium supplements as in non-pregnant women.

Activated vitamin D treatment and calcium supplements are the mainstay of HypoPT treatment during pregnancy and lactation.

Thiazides should be discontinued before conception or once pregnancy is confirmed due to potential risks but could be used with caution in the second and third trimesters after careful risk-benefit assessment.

Therefore, activated vitamin D and calcium supplements are generally reduced immediately postpartum with close biochemical monitoring.

We recommend monitoring ionised calcium and/or albumin-adjusted calcium levels regularly (e.g., every 3–4 weeks) throughout pregnancy and lactation and even more frequently (e.g., weekly) during the 4 weeks before and after delivery, aiming to keep calcium levels at the lower end of the normal range.

DOI: 10.1093/ejendo/lvaf222

View source ↗